188 related articles for article (PubMed ID: 36947201)
1. Utility of targeted gene sequencing to differentiate myeloid malignancies from other cytopenic conditions.
DeZern AE; Goll JB; Lindsley RC; Bejar R; Wilson SH; Hebert D; Deeg J; Zhang L; Gore S; Al Baghdadi T; Maciejewski J; Liu J; Padron E; Komrojki R; Saber W; Abel G; Kroft SH; Harrington A; Grimes T; Reed H; Fulton RS; DiFronzo NL; Gillis N; Sekeres MA; Walter MJ
Blood Adv; 2023 Jul; 7(14):3749-3759. PubMed ID: 36947201
[TBL] [Abstract][Full Text] [Related]
2. Histopathology in the diagnosis and classification of acute myeloid leukemia, myelodysplastic syndromes, and myelodysplastic/myeloproliferative diseases.
Orazi A
Pathobiology; 2007; 74(2):97-114. PubMed ID: 17587881
[TBL] [Abstract][Full Text] [Related]
3. EAHP 2020 workshop proceedings, pediatric myeloid neoplasms.
Leguit RJ; Orazi A; Kucine N; Kvasnicka HM; Gianelli U; Arber DA; Porwit A; Ponzoni M
Virchows Arch; 2022 Oct; 481(4):621-646. PubMed ID: 35819517
[TBL] [Abstract][Full Text] [Related]
4. [Significance of Targeted Sequencing Assay for Patients with Suspected Myeloid Malignancies].
Zhang LJ; Shi YY; Chen Y; Deng Y; Ding YH; Li Z; Chen KK; Ding BH; Wang CL; Yu L; He ZM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Dec; 28(6):1985-1990. PubMed ID: 33283730
[TBL] [Abstract][Full Text] [Related]
5. The utility of a myeloid mutation panel for the diagnosis of myelodysplastic syndrome and myelodysplastic/myeloproliferative neoplasm.
Ibrar W; Zhang W; Cox JL; Cushman-Vokoun A; Fu K; Greiner TC; Yuan J
Int J Lab Hematol; 2021 Dec; 43(6):1501-1509. PubMed ID: 34270867
[TBL] [Abstract][Full Text] [Related]
6. Health-related quality of life and vulnerability among people with myelodysplastic syndromes: a US national study.
Abel GA; Hebert D; Lee C; Rollison D; Gillis N; Komrokji R; Foran JM; Liu JJ; Al Baghdadi T; Deeg J; Gore S; Saber W; Wilson S; Otterstatter M; Thompson J; Borchert C; Padron E; DeZern A; Cella D; Sekeres MA
Blood Adv; 2023 Jul; 7(14):3506-3515. PubMed ID: 37146263
[TBL] [Abstract][Full Text] [Related]
7. The diagnostic utility of targeted gene panel sequencing in discriminating etiologies of cytopenia.
Zheng G; Chen P; Pallavajjalla A; Haley L; Gondek L; Dezern A; Ling H; De Marchi F; Lin MT; Gocke C
Am J Hematol; 2019 Oct; 94(10):1141-1148. PubMed ID: 31350794
[TBL] [Abstract][Full Text] [Related]
8. Predicting cytopenias, progression, and survival in patients with clonal cytopenia of undetermined significance: a prospective cohort study.
Cargo C; Bernard E; Beinortas T; Bolton KL; Glover P; Warren H; Payne D; Ali R; Khan A; Short M; Van Hoppe S; Smith A; Taylor J; Evans P; Papaemmanuil E; Crouch S
Lancet Haematol; 2024 Jan; 11(1):e51-e61. PubMed ID: 38135373
[TBL] [Abstract][Full Text] [Related]
9. Clinical Utility of Targeted Next-Generation Sequencing Assay to Detect Copy Number Variants Associated with Myelodysplastic Syndrome in Myeloid Malignancies.
Jiang L; Pallavajjala A; Huang J; Haley L; Morsberger L; Stinnett V; Hardy M; Park R; Ament C; Finch A; Shane A; Parish R; Nozari A; Long P; Adams E; Smith K; Parimi V; Dougaparsad S; Long L; Gocke CD; Zou YS
J Mol Diagn; 2021 Apr; 23(4):467-483. PubMed ID: 33577993
[TBL] [Abstract][Full Text] [Related]
10. Discordant pathologic diagnoses of myelodysplastic neoplasms and their implications for registries and therapies.
Gorak EJ; Otterstatter M; Al Baghdadi T; Gillis N; Foran JM; Liu JJ; Bejar R; Gore SD; Kroft SH; Harrington A; Saber W; Starczynowski D; Rollison DE; Zhang L; Moscinski L; Wilson S; Thompson J; Borchert C; Sherman S; Hebert D; Walker ME; Padron E; DeZern AE; Sekeres MA
Blood Adv; 2023 Oct; 7(20):6120-6129. PubMed ID: 37552083
[TBL] [Abstract][Full Text] [Related]
11. Clinical Utility of Implementing a Frontline NGS-Based DNA and RNA Fusion Panel Test for Patients with Suspected Myeloid Malignancies.
Bhai P; Hsia CC; Schenkel LC; Hedley BD; Levy MA; Kerkhof J; Santos S; Stuart A; Lin H; Broadbent R; Nan S; Yang P; Xenocostas A; Chin-Yee I; Sadikovic B
Mol Diagn Ther; 2022 May; 26(3):333-343. PubMed ID: 35381971
[TBL] [Abstract][Full Text] [Related]
12. ICUS, IDUS, CHIP and CCUS: Diagnostic Criteria, Separation from MDS and Clinical Implications.
Valent P
Pathobiology; 2019; 86(1):30-38. PubMed ID: 29860246
[TBL] [Abstract][Full Text] [Related]
13. Discriminating myelodysplastic syndrome and other myeloid malignancies from non-clonal disorders by multiparametric analysis of automated cell data.
Kim SY; Park Y; Kim H; Kim J; Kwon GC; Koo SH
Clin Chim Acta; 2018 May; 480():56-64. PubMed ID: 29378171
[TBL] [Abstract][Full Text] [Related]
14. Screening bone marrow samples for abnormal lymphoid populations and myelodysplasia-related features with one 10-color 14-antibody screening tube.
Rajab A; Porwit A
Cytometry B Clin Cytom; 2015; 88(4):253-60. PubMed ID: 25664445
[TBL] [Abstract][Full Text] [Related]
15. MDS overlap disorders and diagnostic boundaries.
Tanaka TN; Bejar R
Blood; 2019 Mar; 133(10):1086-1095. PubMed ID: 30670443
[TBL] [Abstract][Full Text] [Related]
16. The National MDS Natural History Study: design of an integrated data and sample biorepository to promote research studies in myelodysplastic syndromes.
Sekeres MA; Gore SD; Stablein DM; DiFronzo N; Abel GA; DeZern AE; Troy JD; Rollison DE; Thomas JW; Waclawiw MA; Liu JJ; Al Baghdadi T; Walter MJ; Bejar R; Gorak EJ; Starczynowski DT; Foran JM; Cerhan JR; Moscinski LC; Komrokji RS; Deeg HJ; Epling-Burnette PK
Leuk Lymphoma; 2019 Dec; 60(13):3161-3171. PubMed ID: 31111762
[TBL] [Abstract][Full Text] [Related]
17. Progression, transformation, and unusual manifestations of myelodysplastic syndromes and myelodysplastic-myeloproliferative neoplasms: lessons learned from the XIV European Bone Marrow Working Group Course 2019.
Hebeda K; Boudova L; Beham-Schmid C; Orazi A; Kvasnicka HM; Gianelli U; Tzankov A
Ann Hematol; 2021 Jan; 100(1):117-133. PubMed ID: 33128619
[TBL] [Abstract][Full Text] [Related]
18. Diagnosing myelodysplastic/myeloproliferative neoplasms: laboratory testing strategies to exclude other disorders.
Hall J; Foucar K
Int J Lab Hematol; 2010 Dec; 32(6 Pt 2):559-71. PubMed ID: 20670271
[TBL] [Abstract][Full Text] [Related]
19. Myeloid neoplasms with isolated isochromosome 17q represent a clinicopathologic entity associated with myelodysplastic/myeloproliferative features, a high risk of leukemic transformation, and wild-type TP53.
Kanagal-Shamanna R; Bueso-Ramos CE; Barkoh B; Lu G; Wang S; Garcia-Manero G; Vadhan-Raj S; Hoehn D; Medeiros LJ; Yin CC
Cancer; 2012 Jun; 118(11):2879-88. PubMed ID: 22038701
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic, Prognostic, and Predictive Utility of Recurrent Somatic Mutations in Myeloid Neoplasms.
Patel U; Luthra R; Medeiros LJ; Patel KP
Clin Lymphoma Myeloma Leuk; 2017 Jul; 17S():S62-S74. PubMed ID: 28760304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
